Trial Profile
A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Licogliflozin (Primary) ; Empagliflozin
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 03 Apr 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 11 Jan 2022 This trial has been completed in Norway, according to European Clinical Trials Database record.
- 22 Dec 2021 This trial has been completed in Belgium (Global end date: 6 June 2018).